Correction to: Systematic Literature Review to Assess Economic Evaluations in Spinal Muscular Atrophy (SMA)

Noman Paracha¹ · Pollyanna Hudson² · Stephen Mitchell² · C. Simone Sutherland¹

Published online: 26 February 2022
© The Author(s) 2022

Correction to: PharmacoEconomics (2021)
<https://doi.org/10.1007/s40273-021-01095-6>

In Table 1 of this article, the data in the 8th column of the intervention price row was incorrectly published as

OA: list price \$2,125,000
Nus: NR

It should have been

OA: NR
Nus: list price of SEK 800,757 per vial (€78,300)

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by-nc/4.0/>.

The original article can be found online at <https://doi.org/10.1007/s40273-021-01095-6>.

✉ C. Simone Sutherland
simone.sutherland@roche.com

¹ F. Hoffmann-La Roche Ltd, Basel, Switzerland

² Mtech Access Limited, Bicester, Oxfordshire, UK